- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02272855
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
A Phase II Study of Combination Treatment With HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Patients With Stage IIIB, Stage IIIC, or Stage IV Unresectable or Metastatic Malignant Melanoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is designed to assess efficacy and safety with repeated administration of intratumoral injections of HF10 at 1x10^7 TCID50/mL in combination with intravenous infusions of 3mg/kg ipilimumab. This is a single arm, open label Phase II trial, to evaluate the efficacy, safety and tolerability of HF10 treatment in combination with administration of the immunologic checkpoint inhibitor, ipilimumab (anti-CTLA-4 monoclonal antibody). The study population will include patients with Stage IIIB, IIIC or IV unresectable or metastatic malignant melanoma who are ipilimumab-eligible.
Patients will receive the dose of 1 x 10^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) + ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
Following combination therapy, patients may continue to receive the same dose level of HF10 (1 x 10^7 TCID50/mL) alone for up to an additional 13 injections (total of 19 injections = 1 year) if they have tolerated the study treatment, are responding, have stable disease, or have progressive disease that is not clinically significant in the judgment of the Investigator.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94115
- Clinical Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Clinical Site
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Clinical Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18015
- Clinical Site
-
Hershey, Pennsylvania, United States, 17033
- Clinical Site
-
-
Texas
-
Dallas, Texas, United States, 75230
- Clinical Site
-
Houston, Texas, United States, 77030
- Clinical Site
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Clinical Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have Stage IIIB, IIIC or IV melanoma, which is unresectable/unresected or histologically confirmed diagnosis of metastatic malignant melanoma.
- Patients must have measurable non-visceral lesion(s) that are evaluable by the modified World Health Organization (mWHO) criteria and immune-related response criteria (irRC).
- Patients must be ≥ 18 years of age.
- Patients must have a life expectancy ≥ 24 weeks.
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Patients must have adequate hepatic function, defined as
- Total bilirubin levels ≤ 1.5 x upper limit of normal [ULN] (except for patients with Gilbert's Syndrome, who must have a total bilirubin of less than 3.0 mg/dL)
- AST/ALT levels ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present.
- Patients must have adequate renal function, defined as serum creatinine ≤ 1.5 x ULN or creatinine clearance (calculated) ≥ 60 mL/min/1.73 m2 for patients with creatinine > 1.5 x ULN.
Patients must have adequate bone marrow function, defined as
- Absolute neutrophil count ≥1,500/µL and
- Platelet count ≥ 75,000/ µL
- Patients must have no known bleeding diathesis or coagulopathy that would make intratumoral injection or biopsy unsafe.
- Patients must be ipilimumab-eligible. (This includes: 1) patients previously untreated with ipilimumab; 2) patients previously treated (more than 1 year previously) with ipilimumab using a route of administration other than intravenous infusion; and 3) patients previously treated with antitumor agents other than intravenous ipilimumab).
- Men and women of childbearing potential must agree to use adequate contraception from the time of consent through 30 days after final study treatment.
- Females of childbearing potential must have a negative urine or serum pregnancy test within one week prior to start of treatment.
- Patients must be able to understand and willing to sign a written informed consent document.
Exclusion Criteria:
- Patients receiving chemotherapy or radiotherapy within 4 weeks of injection of HF10, or history of Grade 4 adverse events or presence of adverse events Grade 2 or greater, except alopecia, resulting from anticancer agents administered more than 4 weeks prior to HF10 injection.
- Patients receiving anti-herpes medication within 1 week prior to initiating HF10 treatment.
- Patients with a history of significant tumor bleeding, or coagulation or bleeding disorders.
- Patients with target tumors that could potentially invade a major vascular structure (e.g., innominate artery, carotid artery), based on unequivocal imaging findings.
- Patients with Grade 2 or greater pre-existing neurologic abnormalities (CTCAE version 4.0), including Grade 2 or greater peripheral neuropathy caused by previous treatments.
- Patients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection are excluded.
- Medical history of autoimmune disease (e.g., Crohn's disease, ulcerative colitis) or other diseases requiring systemic glucocorticoid or immunosuppressive therapy.
- Patients who were previously treated with ipilimumab administered by intravenous infusion.
- Concurrent use of any other investigational agents.
- Patients with active CNS metastases or carcinomatous meningitis, except patients with CNS lesions that have been treated and have no evidence of progression in the brain on CT/MRI for ≥ 3 months.
- Pregnant or breastfeeding women; women desiring to become pregnant within the timeframe of the study are also excluded.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, as determined by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HF10 plus ipilimumab
|
Patients will receive the dose of 1 x 10^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Best overall response rate (BORR)
Time Frame: at 24 weeks
|
at 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event Summaries, Vital Signs, and Laboratory Parameters as a Measure of Safety and Tolerability
Time Frame: until Week 24
|
Adverse events will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0).
|
until Week 24
|
Objective response rate (ORR)
Time Frame: at Weeks 12, 18, and 24
|
at Weeks 12, 18, and 24
|
|
Progression-free survival (PFS)
Time Frame: for 1 year
|
for 1 year
|
|
Durable response rate (DRR)
Time Frame: for 1 year
|
for 1 year
|
|
1-year survival rate
Time Frame: at 1 year
|
at 1 year
|
|
Accumulation of Lymphocytes in the Tumor by using Core Biopsy Samples
Time Frame: pre-treatment screening and Week 24
|
pre-treatment screening and Week 24
|
|
Change in Cytokine Profiles by using Peripheral Blood Samples
Time Frame: pre-treatment screening and Week 24
|
pre-treatment screening and Week 24
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Andtbacka, University of Utah
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Ipilimumab
Other Study ID Numbers
- T14-10682
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Melanoma
-
National Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant MelanomaUnited States
-
Grupo Español Multidisciplinar de MelanomaGlaxoSmithKlineCompletedMalignant Melanoma Stage IV | Malignant Melanoma Stage IIIcSpain
-
Centre Hospitalier Universitaire de NiceUnknownMalignant Melanoma Stage III | Malignant Melanoma Stage IV
-
Hoffmann-La RocheCompletedMalignant Melanoma, CancerHungary
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsUnited States, South Africa, Croatia, Brazil, Egypt
-
Lynn E. Spitler, MDGenentech, Inc.; Celgene CorporationCompletedMetastatic Malignant MelanomaUnited States
-
National Cancer Institute (NCI)GlaxoSmithKline; Novartis PharmaceuticalsActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...United States
-
Steinar AamdalTerminatedMetastatic Malignant MelanomaNorway
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsBelgium, Spain, Germany, Netherlands, Finland
-
Eli Lilly and CompanyCompletedMetastatic Malignant MelanomaUnited States
Clinical Trials on HF10 plus Ipilimumab
-
Takara Bio Inc.CompletedMelanoma Stage IV | Melanoma Stage IIIJapan
-
Takara Bio Inc.CompletedMalignant Melanoma | Carcinoma of the Breast | Squamous Cell Carcinoma, Skin | Refractory Head and Neck CancerUnited States
-
Rush University Medical CenterWithdrawnChronic Low-back Pain | Peripheral Neuropathy | CRPS
-
Nevro CorpActive, not recruitingPainful Diabetic NeuropathyUnited States
-
Takara Bio Inc.Completed
-
Nevro CorpActive, not recruiting
-
Guy's and St Thomas' NHS Foundation TrustKing's College London; University of Oxford; University of Liverpool; National... and other collaboratorsUnknownChronic Low Back Pain | Neuropathic Pain | Refractory PainUnited Kingdom
-
Italian Network for Tumor Biotherapy FoundationBristol-Myers Squibb; Astex Pharmaceuticals, Inc.Not yet recruitingMelanoma | Non Small Cell Lung CancerItaly
-
Dana-Farber Cancer InstituteBristol-Myers Squibb; Genentech, Inc.CompletedMelanomaUnited States
-
Nevro CorpTerminated